Our study provides compelling evidence that the modulation of FOXP3 gene expression in OVCAR3 cells by rosmarinic acid and doxorubicin represents a promising avenue for enhancing therapeutic strategies against ovarian cancer. The gene discussed is FOXP3; the disease is ovarian cancer.